Clinical Trial Detail

NCT ID NCT03396497
Title Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Lycera Corp.
Indications

lung non-small cell carcinoma

Therapies

LYC-55716 + Pembrolizumab

Age Groups: senior adult

Additional content available in CKB BOOST